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Summary.-Growth curve measurements on the EMT6 tumour following treatment
with cyclophosphamide indicate a growth delay of about 3 days for each 100 mg/kg
of the drug. Tumours treated whilst still microscopic show a rather longer delay
for the same dose. Data for the surviving fraction of cells in the tumours measured
byinvitroplating at2 haftercyclophosphamide are notcompatible with the measured
growth delay and realistic values for the doubling times of surviving clonogenic cells.
It is concluded that there is considerable " repair of potentially lethal damage ",
and that there is probably no single time after cyclophosphamide treatment at which
the surviving fraction of cells can be correctly measured by the in vitro plating
technique. Cell loss from cyclophosphamide-treated tumours is increased only
slightly over that from untreated tumours, and the regeneration of surviving cells is
very rapid. In this situation, only marginal regressions in tumour volume are
caused by the highest doses of the drug.
The response of a solid tumour to
chemotherapy may be assessed either in
terms of changes in the size of the tumour
following treatment or by measuring the
surviving fraction of cells in a suspension
prepared from the tumour after treatment.
In the clinical situation, it is only possible
to use the former method, and the inci-
dence of " 50% regression in tumour
volume " is frequently used as a criterion
for assessment of treatment. It is, how-
ever, well established that the changes in
tumour volume following therapy are
dependent upon the rate of cell loss from
the tumour and the proliferative capacity
of surviving cells as well as upon the cell
killing by the agent. On the other hand,
preparation of a cell suspension from a
treated tumour involves disruption of the
tumour matrix and alteration of the post-
treatment environment of the cells. It is
known that this process can influence the
measured surviving fraction by, amongst
other things, inhibition of repair of
potentially lethal damage (Hahn et al.,
1973; Twentyman and Bleehen, 1975).
We have, therefore, begun to investi-
gate the response to chemotherapy of a
solid murine tumour which is amenable to
estimation of cell surviving fraction by
in vitro plating, and to study the relation-
ship between the various measurable
parameters ofresponse. In this paper we
report results of such studies with cyclo-
phosphamide.
MATERIALS AND METHODS
The tumour system.-The tumour used in
these studies was the EMT6/VJ/AC subline
of the EMT6 tumour originally described by
Rockwell, Kallman and Fajardo (1972).
The methodology of making cell suspensions,
growing the cells in vitro, and measurement of
surviving fraction by in vitro cloning, as used
in this laboratory, have been described
previously (Twentyman and Bleehen, 1974,
1975). Unless stated otherwise, tumours
were inoculated intra-dermally as 4x 104SENSITIVITY OF TUMOURS IN VIVO. I. CYCLOPHOSPHAMIDE
cells into the flanks of BALB/c mice 12-20
weeks of age. Male mice were used in the
majority of experiments, but females
were used in some of the repeats. No
differences were seen between the results
with the two sexes. Tumour volumes were
determined bytaking 3 caliper measurements,
mutually at right angles, and using the
equation derived by Watson (1976).
Experiments were started uponthe day on
which the individual tumour volume first
exceeded either 50 mm3 (Days 8-10 after
inoculation) or 300 mm3 (Days 14-16 after
inoculation).
The growth of the EMT6 tumour in the
lungs following i.v. injection of 105 cells has
been recently described by us (Twentyman
and Bleehen, 1976), our investigation having
been based on the original study by Brown
(1974).
In order to determine the doubling time
of the solid tumour at its microscopic stage
(i.e. up to a size of 106 cells), experiments
were carried out in which groups of 10 mice
received varying numbers of live cells.
Inocula of less than 106 live cells were
admixed with 106 radiation-killed (HR) cells.
No tumours were produced by inocula of
106 HR cells alone.
In some experiments, cells prepared from
tumours were plated out into both fresh
medium and " plateau medium ". The
" plateau medium " was produced by allow-
ing fresh medium to overlie a confluent in
vitro culture of EMT6 cells for a period of
24 h. This medium was then removed,
centrifuged at 3000 rev/min for 10 min and
passed through a 02-,um millipore filter
before use. Cells remained in the fresh or
plateau medium for 48 h after plating, at
which time the medium from both sets of
plates was carefully removed and replaced
by fresh medium. The plates were then
returned to the incubator.
Cyclophosphamide (CY).-This was kindly
supplied as pure powder by Ward Blenkinsop
Limited. The powder was dissolved in
sterile Hanks' solution immediately before
injection, and the solution was injected i.p.
in a volume of 0-2-0-6 ml.
Hydroxyurea (HU).-A double dose of
hydroxyurea, each dose being 1 mg/g, was
used to obtain an estimate ofthe proliferative
fraction of cells in tumours both before and
after treatmzent with cyclophosphamide. A
preliminary experiment was carried out on
rapidly growing tumours 3 days after
inoculation of 4 x 104 cells, with different
time intervals between the 2 doses. In all
subsequent experiments a time interval of
7 h was used.
Cell loss.-Measurements were carried
out using [1251] Iododeoxyuridine (125IUdR)
(lOOmCi/mg) obtained from the Radio-
chemical Centre, Amersham. On the day
upon which its tumour reached 50 mm3, each
mouse received 0-1 ,Ci/g of 125IUdR i.p.
After 48 h to allow equilibration of label,
half the animals received 200 mg/kg of
cyclophosphamide. At various times after-
wards, mice were killed and their entire
tumours removed. Each tumour was then
carefully cleaned of connective tissue, blotted
dry, placed in a plastic vial and subsequently
counted on a well-type scintillation counter.
Counting corrections were made for the vol-
ume of tumour in each vial.
RESULTS
Tumour volume data
The changes in tumour volume follow-
ing treatment with CY at 50 mm3 are
shown in Fig. 1. The regrowth curves are
all closely parallel to the control curve,
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FIG. 1.-Change in tumour volume with time
following various single closes of CY. Tum-
ours treated at a volume of 50 mm3.
Points are mean tumour volumes for groups
of 12 mice. Error bars at 13 days indicate
the standard error of the mean.
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TABLE I.-Growth Delay Induced by Cyclophosphamide in Microscopic Tumours
Cyclophosphamide dose (mg/kg)
,dministration 0
9, 9, 9, 9, 9,
2 days after 9, 9, 9, 9, 10,
inoculation 10, 10, 10, 10, 10,
12, 12,
(9)
100
15, 16, 16, 16, 16,
16, 16, 18, 18, 18,
19, 22, 23, 26, 29,
29, TC,
(18)
11, 13, 13, 14, 14,
15, 15, 15, 15, 15,
15, 16, 16, 16, 17,
17, 17, 17,
(15
200
20, 20, 20, 20, 21,
21, 21, 22, 23, 23,
24, 26, 27, 27, 30,
35, TC, TC, TC,
(22.5)
17, 17, 17, 18, 18,
19, 19, 19, 19, 19,
20, 20, 21, 21, 21,
22, 22, 22,
(19)
300
19, 23, 24, 24, 24,
24, 24, 26, 27, 27,
31, 31, 33, 38, 38,
TC, TC,
(26)
20, 21, 22, 22, 22,
22, 23, 24, 24, 24,
24, 24, 24, 25, 26,
27, 27, 27,
(24)
Figures are times in days for individual tumours to reach 100 mm3.
TC = animal alive and tumour-free at 100 days after treatment.
Figures in parentheses are the medians of the groups.
and the growth delay produced is almost
exactly 3 days for each 100 mg/kg of CY.
At no time after doses of 100 and 200 mg/
kg does the tumour volume fall below that
at the time of treatment, and for 300
mg/kg, the minimum volume is about
75% of the mean pretreatment value.
For tumours treated at a size of 300 mm3,
the regrowth curves for 200 and 300
mg/kg were not parallel to the curve for
untreated tumours. This was largely due
to the fact that these high doses produced
a necrotic region within the tumour
extending towards the skin, with surface
ulceration and subsequent contraction of
the tumour mass. This pathology is
typical of transplanted tumours growing
intradermally where growth is lateral and
to a depth, with a progressive deteriora-
tion of the vasculature to the central part
of the tumour adjacent to the skin. The
tumours do, however, then regrow rapidly.
Similar curves were obtained in a repeat
experiment. Between tumour volumes of
400 and 800 mm3, where the departure
from parallel regrowth is relatively small,
the growth delay due to the CY is again
very close to 3 days for each dose incre-
ment of 100 mg/kg.
Microscopic tumours
The growth delay induced by CY in
microscopic tumours treated at 2 or 5 days
after inoculation is shown in Table I.
The data are pooled from 2 identical
experiments. It may be seen that the
growth delay for the microscopic tumours
is greater than that for the larger tumours,
i.e. about 5-6 days delay per 100 mg/kg
ofCY.
In vitro plating offlank tumours
The results of plating out cells from
50 mm3 tumours at various times after
administration of CY are shown in Fig. 2.
Following a dose of 200 mg/kg (Fig. 2) the
number of colonies per cell plated is
reduced by more than 103 when plating is
carried out 2 h after drug administration.
If, however, plating is delayed until 48 h
after drug administration, the reduction
in surviving fraction is only about
ten-fold. Survival then gradually in-
creases to reach normal levels 5-6 days
after CY. The data for plating out
following 100 or 300 mg/kg of CY again
show a very large change in measured
surviving fraction between 2 h and 48 h,
being by a factor of around 15 at 100
mg/kg and around 100 at 300 mg/kg.
For tumours treated at 300 mm3, the
results are shown in Fig. 3. The initial
(2-h) surviving fraction appears to be
significantly higher at all 3 doses of CY
than were seen for 50 mm3. By 48 h,
however, the values obtained are very
similar to those seen for corresponding
drug doses at the smaller tumour size.
Time ofCY
a
5 days after
inoculation
as
above
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Fi(.2. Change in surviving fraction of cells
from solid tumours with time between CY
administration and preparation of cell
suspension. Tumours treated at a volume
of 50 mm3. 0-100 mg/kg CY; A
200 mg/kg CY; 0 300 mg/kg CY.
Horizontal (lotted line shows lower limit of
measuremenit in this assay system. Each
point represents the mean value of sur-
viving fraction for groups of 4 mice within
the same experiment. Error bars show
the standard error of the mean. The scale
of the abscissa is broken.
The approximate factors between the 2-h
and 48-h results are five-, ten- and twenty-
fold at 100, 200 and 300 mg/kg respec-
tively.
In one series of experiments at both
tumour sizes, the procedure for making
the cell suspension from solid tumours was
particularly carefully controlled, in order
to be as far as possible identical in all
cases. The total number of viable tum-
our cells in the final suspension was
determined for several tumours, both
untreated and removed 2 or 48 h after
CY (200 mg/kg). The mean cell yields
were 4-6, 4-4 and 4-7 x 108 cells/tumour
respectively.
Days
FPi.. 3.-Change in surviving fraction of cells
from solid tumours with time between CY
administration and preparation of cell
suspension. Tumours treated at a volume
of 300 mm3. Otherwise as in Fig. 2.
In vitro plating of lung tumours
The data obtained for plating out cells
obtained from tumour-bearing lungs at
various times after treatment with CY are
shown in Fig. 4. In these experiments,
the CY was administered 9 days after
tumour inoculation. For 100 mg/kg the
mean value of a little below 10-3 obtained
at 2 h rises to a mean value of about
5 x 10-2 at 48 h, i.e. by a factor of 50-
100. At 200 mg/kg the survival is below
the lower limit of the technique (deter-
mined by fibroblast overgrowth if too
many normal lung cells are plated into a
dish), if measured at 2 h or 24 h after CY
treatment, but has risen to a mean value
of 5 x 10-4 by 48 h.
In vitro plating: effect of medium
Nine separate cell suspensions from
tumours removed 2 h after treatment with
z
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n
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FIG. 4. Change in surviving fraction of
tumour cells growing in the lung with time
between CY administration and prepara-
tion of cell suspension. Mice treated at 9
days after inoculation of tumour cells.
0 1O0 mg/kg CY; A 200 mg/kg CY.
Horizontal dotted line shows lower limit of
measurement in this assay system. Each
point represents the mean value of sur-
viving fraction for groups of 4 mice within
the same experiment. Error bars show the
standard error of the mean.
CY (200 mg/kg) at a size of 50 mm3 were
plated into both depleted plateau medium
and into fresh medium with a subsequent
change of all plates to fresh medium after
48 h. The surviving fraction for fresh
medium was 0 086 i 0-023 (mean ± s.e.),
whereas in plateau medium the surviving
fraction was 0 28 + 0 05, i.e. higher by a
factor of 3 3. No difference was seen in
the plating efficiency of cells from un-
treated tumours plated into the 2 media.
Growth rate of microscopic tumours
The times to reach a volume of 200
mm3 for tumours growing from different
numbers of live cells are shown in Fig. 5.
10
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FiG. 5.-Dependence of time for tumours to
reach a volume of 200 mm3 on number of
live cells inoculated on Day 0. Inocula of
105 live cells or less were admixed with 106
radiation-killed cells. The points represent
the median values for groups of 8 mice.
Two separate experiments are shown.
The line is fitted by eye and corresponds to
a tumour doubling time of 23 h.
The best line through the points indicates
a doubling time for the tumour cell
population of about 23 h.
Cell loss
The results of 2 separate experiments
in which 125IUdR was used to study the
effect ofCY on cell loss are shown in Fig. 6.
A period of 48 h was allowed between
administration of activity and first
measurement, and the amount of label
remaining in the acid soluble fraction
should therefore have been only a few per
cent.
It may be seen that the overall rate of
loss of label is increased by the admini-
stration of CY, the activity remaining at
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FIG. 6.-Loss of 125IUdR activity in solid
tumours with time. Values are normalized
to 100% at time 0 which was 48 h after
administration of 125IUdR to tumours at a
volume of 50 mm3. Closed symbols-
control mice; opensymbols-micereceiving
CY (200 mg/kg) at time 0. Different shape
ofsymbols represent different experiments.
Each represents the mean ± s.e. for a group
of 5-8 mice.
6 days after treatment being about 25%
with the drug and 45% without.
Split-dose hydroxyurea: growth curves
The effect upon tumour growth of a
double dose of HU (each dose being
1 mg/g) given 3 days after tumour inocu-
lation is shown in Fig. 7. With an
interval of 3 h between doses, little growth
delay is produced. An interval of 12 h
produces a delay of about one day, but an
interval of 7 h produces a delay of about
3 days. This result is in agreement with
the findings ofHodgson etal. (1975) forthe
effect of split-dose HU on the survival of
regenerating haemopoietic colony-forming
cells in the spleens of BALB/c mice. The
effect ofa double dose ofHU (each dose of
15
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FIG. 7.-Change in volume of solid tumours
with time. *-control tumours; A-
mice given 2 doses of HU (each 1 mg/kg)
separated by 3 h on Day 3 after tumour
inoculation; A-dose separation = 7 h;
0-dose separation = 12 h. Each point
represents the mean tumour volume for
groups of 8 mice. Error bars shown at
Day 15 represent the standard error of the
mean.
1 mg/g and separated by 7 h) upon
control and regenerating tumours is shown
in Fig. 8.
A double dose of HU given on the day
upon which tumours reach 50 mm3 has
little effect upon tumour growth. If,
however, the HU is given at 3 days after
inoculation of the tumours, a delay of
about 4 days compared with control
tumours is produced. A dose of CY
(200 mg/kg) given upon reaching 50 mm3
produces agrowth delayofabout 5-6 days,
which is in agreement with the results
shown in Fig. 1. If the double dose of
HU is given at 3 days after CY, an
additional delay of around 2-3 days is
produced. In Table II, the data from
this experiment and 2 identical repeats
"I
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FIG. S.-Change in volume of solid tumours
with time. 0-control tumours normal-
ized to have a volume of 50 mm3 at Day 0;
O as control, but receiving 2 doses ofHU
(each dose = 1 mg/g and separated by 7 h)
on Day 0 (i.e. at a volume of 50 mm3); A-
as control, but receiving CY (200 mg/kg)
on Day 0; A- as control but receiving C Y
(200 mg/kg) on Day 0 and 2 x HU on Day
3; * -a group inoculated with the tum-
our at the same time as the control group
but receiving 2 x HU 3 days after tumour
inoculation. Each point is the mean value
of tumour volume for a group of 10 mice.
Bars at 7 days show s.e. of mean.
are summarized. The growth delay has
been quantified by measuring the dif-
ference in time to reach 200, 400 and 600
mm3 and the mean value for the 3 experi-
ments calculated. It may be seen that
the value for 2 x HU at 3 days after CY
lies approximately midway between the
delay produced at 3 days after inoculation
and at 50 mm3 for untreated tumours.
DISCUSSION
It is very clear from the data presented
here for the in vitro plating assay after
treatment of the EMT6 tumour with
cyclophosphamide, that a wide range of
estimates of surviving fractions may be
obtained, dependinguponthetime selected
for assay. As an example we may con-
sider the response of 50-mm3 tumours to
200 mg/kg, where the mean surviving
fractions are 5 x 10-4 at 2 h, 2 x 10-3
16 at 24 h and 4 X 10-2 at 48 h. Afactor of
about 100 is therefore seen between 2 and
48 h. There is no significant difference in
cell yield from tumours at these times,
and furthermore the data for 125IUdR loss
indicates only a small difference in
removal of label from untreated and CY-
treated tumours. We can therefore re-
gard the selective loss of CY-killed cells
from the tumour over a period of 48 h
as a minimal factor. Selective prolifera-
tion of non-killed cells is an alternative
factor which could influence the result
TABLE II.-Tumour Growth Delay Produced by Split-Dose Hydroxyurea
Tumours treated at
50 mm3
200 400 600
0*0 -1*5 -1*1
1-2 1-2 2-0
1-3 1-2 0-2
0-5
Tumours treated at
3 days after
inoculation
200 400 600
4-5 3-0 3-2
3-4 4-8 5-3
4-6 4-4 5-0
4-2
Tumours treated at
3 days after CY
(200 mg/kg) given
at 50 mm3
200 400 600
1-3 1-0 2-5
3-2 2-4 1-9
1-2 3-0 2-0
2-1
All growth delays given in days.
Hydroxyurea given in 2 doses each of 1 mg/g with an interval of 7 h between doses.
Growth delay
estimated at a
size of (mm3)
Experiment A
Experiment B
Experiment C
Mean delay (3
experiments
estimated at 3
different sizes)
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and which would not necessarily be
detectable by significant changes in the
cell yield, as only a few per cent of the
tumour cell population need be involved.
We have, however, to explain an increase
by a factor of 100 over 48 h. The
doubling time of untreated 50-mm3 tum-
ours is 40-50 h. This is, however, much
longer than the cell cycle time which,
from the available data for other EMT6
sublines (Rockwell et al., 1972; Watson,
1976) probably lies in the range of 16 to
19 h, with a growth fraction of . 5000
and significant cell loss. If it is assumed
that the surviving clonogenic cells are a
representative fraction ofthe total number
of clonogenic cells, then it is difficult to
see why the doubling time of the sur-
vivors should be any shorter than that
of the untreated tumour at a given
size. This might occur if there were a
sudden large-scale cell loss and rearrange-
ment of tumour structure, but this does
not appear to happen. If, on the other
hand, the surviving cells are able to
respond to the new reduced size of their
own population, they may do so by
doubling in a manner akin to that of
tumours growing from a small inoculum
in the presence of radiation- (or drug-)
killed cells. In this situation, as shown
in Fig. 5, the doubling time is about 23 h.
If the experiment using 2 doses of HU
and observing the growth-curve delay is
valid, it appears that the doubling time of
surviving cells (measured at 3 days after
CY) lies somewhere between these 2
possibilities. If, however, for the sake of
argument we regard the lower estimate of
23 h as the shortest realistic doubling
time and further assume that
(a) doubling of surviving cells begins
essentially immediately after CY treat-
ment, i.e. no growth delay induced by the
drug, and
(b) accelerated growth of survivors
continues right up until the time that the
pretreatment tumour volume is reached;
the maximum number of doublings occur-
ring during the period of 6 days growth
delay after 200 mg/kg is about 6, which is
equivalent to a surviving fraction of
around 1-500. Furthermore, the increase
over the first 48 h can only be by a factor
of 4. Both these figures are incompatible
with the data for in vitro plating. It is
possible that the regrowth of tumours
after CY treatment is accelerated by
immune depression of the host. We do
not believe this to be true, however, as
there is no difference in the rate ofgrowth
of the EMT6 tumour in animals treated
with CY before inoculation and in un-
treated controls.
We are therefore left with the possi-
bility that repair of potentially lethal
damage (PLD) (as suggested by Hahn et
al., 1973) is in part responsible for the
change in observed surviving fraction
between 2 and 48 h. In their original
study of the EMT6 tumour, Hahn et al.
(1973) found a difference by a factor of
4-5 in the measured surviving fraction at
2 and 24 h after 200-300 mg/kg of CY.
Using the B16 melanoma, however, Hill
and Stanley (1975) found no difference in
surviving fraction measured 2 or 22 h
after the drug. In the Lewis lung
tumour, Steel and Adams (1975) used
times of 3 h and 16 h after CY, and found
no difference between these. We must
therefore conclude either that EMT6 is the
only one of these three different tumours
to carry out PLD repair after CY, or else
that for B16 and Lewis lung the PLD
repair occurs between 24 and 48 h after
drug treatment. There is certainly a
strong indication from the data presented
in this paper that PLD repair in the EMT6
tumour continues after 24 h.
The effect of this early increase in
measured surviving fraction following CY
is very important when considering the
relative effect of the drug upon different
tumour sizes. It may be seen that the
surviving fraction measured at 2 h is
significantly lower in 50-mm3 than in
300-mm3 tumours, for all drug doses. By
48 h, however, the differential is largely
lost, due apparently to a greater repair of
PLD in the smaller tumours. This finding
is in agreement with the observation that
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the growth delay induced by the same
dose of CY is similar at 2 tumour sizes.
For tumour cells growing in the lungs, the
response measured at either 2 h or 48 h
appears to be somewhat greater than in
the solid tumour. In our previous study,
in which we looked at lower doses of CY
(up to 140 ,ug/ml) we did not see much
difference between the response of small
tumours and lung nodules measured 2 h
after CY. The spread of results in this
type ofassayis, however, sufficiently great
to make the 2 results compatible. The
delay in tumour growth produced by CY
given to animals bearing microscopic
tumours is, however, greater than that
seen in the macroscopic tumours, adding
weight to the argument that a degree
of tumour-size dependence occurs with
CY.
Whichever is the true value for the
surviving fraction of cells in solid tumours
after CY treatment, it is clear that the
change in tumour size is a very poor guide
to this. Even after 300 mg/kg at 50 mm3
the maximum reduction in tumour volume
is 25%, and at lower doses no reduction at
all occurs. This is probably due to the
short time course of regeneration of
surviving cells compared with the rate of
cell loss following drug treatment.
The points which we have made
regarding the nature of " PLD " following
treatment of the EMT6 tumour with
bleomycin (Twentyman and Bleehen,
1975) apply largely to cyclophosphamide
also. The expression " repair of PLD "
refers only to the observed phenomenon
of increased surviving fraction with de-
layed subculture rather than carrying any
implication regarding mechanisms. It is
clear that the effect following CY occurs
over a longer period than that follow-
ing bleomycin or X-irradiation (Little
et at., 1973; Hahn et al., 1974) and also
that the effect occurs to at least as great
an extent in small tumours as in large
ones.
With " PLD repair " extending over a
period of at least 48 h, by which time the
proliferation of surviving cells is probably
well under way, there is no time at which
the absolute value of" surviving fraction "
can correctly be measured. Unless some
way of inhibiting either PLD repair or
proliferation of survivors, but not both, is
found, the time at which " surviving
fraction" determinations are made is
largely arbitrary. It seems to us, at this
stage, that " growth delay " may be the
most relevant basis for comparing the
effectiveness of various treatment modali-
ties upon the EMT6 tumour. We need,
however, to collect much more data
following treatment with different agents,
before firm conclusions can be reached.
I wish to thank Professor N. M.
Bleehen for his continued support and for
discussion of the data, and Mrs Jane
Donaldson for her expert technical assis-
tance.
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